No Prescription |
 |
 | ||
|
Intazide Colazal |
|
| ||
No Prescription » Prescription Drugs 9 » Intazide Colazal Balsalazide is used to treat ulcerative colitis a condition in which the bowel is inflamed. Balsalazide is an anti-inflammatory drug. It is converted in the body to mesalamine and works by reducing bowel inflammation diarrhea rectal bleeding and stomach pain.Balsalazide comes as a capsule to take by mouth. It is usually taken three times a day. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Take balsalazide exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.Balsalazide is usually taken for 8 weeks but it may be taken for up to 12 weeks. Continue to take balsalazide even if you feel well. Do not stop taking balsalazide without talking to your doctor. Buy Intazide Colazal and other Prescription Drugs 9 products online at Medstore. Buy Online at Medstore - Click Here!
About Intazide Colazal: Product Type: Prescription Drugs 9 Intazide ( Colazal Generic Balsalazide ) Intazide (Colazal Generic Balsalazide) Colazal Generic Balsalazide 750mg 2 x 50 Capsules 4 x 50 Capsules 50 Capsule Colazal Generic Balsalazide Intazide
View more Prescription Drugs 9 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
